comparemela.com

Latest Breaking News On - Mediated nephritis - Page 1 : comparemela.com

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United-states
Japan
South-korea
Taiwan
American
Pushkar-mutha
Mariat-bourlon
Tycel-jovelle-phillips
Tony-mok
Lin-wang
Peter-robert-galle
Charlene-mantia

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

China
Cambridge
Cambridgeshire
United-kingdom
Canada
United-states
American
Chinese
Susan-galbraith
Dave-fredrickson
Daiichi-sankyo-inc
Daiichi-sankyo-company

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial .

United-states
China
United-kingdom
Amsterdam
Noord-holland
Netherlands
Japan
Cambridge
Cambridgeshire
America
American
Suresh-senan

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting .

Kunlun
Zhejiang
China
Spain
Australia
Canada
United-states
Sweden
Japan
United-kingdom
San-francisco
California

Coherus Announces U.S. Launch of LOQTORZI™

– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for.

United-states
Mike-beyer
Coherus-biosciences
John-hopper
Paul-reider
Jami-taylor
Denny-lanfear
Exchange-commission
Administration-in-prescribing-information
Founder-of-the-patient-activation-group
Neck-cancer-foundation
Red-house-communications

vimarsana © 2020. All Rights Reserved.